altastaph

a Staphylococcus aureus serotype 5 and 8 vaccine induced hyperimmune polyclonal antibody

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        altastaph: 5
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        altastaph: 5
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        altastaph: 5

Experts

1.	Kaufman, David A: 2 articles (04/2015 - 04/2009)
2.	Patel, Manisha: 1 article (04/2015)
3.	Shah, Prakeshkumar S: 1 article (04/2009)
4.	Dicpinigaitis, Peter V: 1 article (12/2007)
5.	Fowler, Vance G: 1 article (12/2007)
6.	Holley, H Preston: 1 article (12/2007)
7.	Levine, Donald P: 1 article (12/2007)
8.	Lutz, Jon: 1 article (12/2007)
9.	Rupp, Mark E: 1 article (12/2007)
10.	Veney, Naomi: 1 article (12/2007)

Related Diseases

1.	Infections 04/01/2015 - "The ability of antistaphylococcal immunoglobulins, Altastaph and INH A-2, to augment the neonatal immune system to prevent infections has been studied and evaluated in a 2009 Cochrane review. " 04/15/2009 - "There were no significant differences noted in the risk of Staphylococcal infection between INH A-21 vs. placebo (typical RR 1.07, 95% CI 0.94, 1.22) or Altastaph vs. placebo (RR 0.86, 95% CI 0.32, 2.28); the risk of other bacterial infection between INH A-21 vs. placebo (typical RR 0.87, 95% CI 0.72, 1.06) or Altastaph vs. placebo (RR 0.93, 95% CI 0.53, 1.64); or the risk of any infection between INH A-21 vs. placebo (RR 1.00, 95% CI 0.91, 1.09) or Altastaph vs. placebo (RR 0.93, 95% CI 0.54, 1.62). " 05/01/2006 - "aureus infections are caused by capsular polysaccharide (CPS) types 5 and 8. Altastaph is a polyclonal investigational human immunoglobulin G (IgG) with high levels of opsonizing S. "
2.	Staphylococcal Infections 04/15/2009 - "Antistaphylococcal immunoglobulins (INH A-21 and Altastaph) are not recommended for prevention of staphylococcal infections in preterm or VLBW neonates. " 04/15/2009 - "There were no significant differences noted in the risk of Staphylococcal infection between INH A-21 vs. placebo (typical RR 1.07, 95% CI 0.94, 1.22) or Altastaph vs. placebo (RR 0.86, 95% CI 0.32, 2.28); the risk of other bacterial infection between INH A-21 vs. placebo (typical RR 0.87, 95% CI 0.72, 1.06) or Altastaph vs. placebo (RR 0.93, 95% CI 0.53, 1.64); or the risk of any infection between INH A-21 vs. placebo (RR 1.00, 95% CI 0.91, 1.09) or Altastaph vs. placebo (RR 0.93, 95% CI 0.54, 1.62). " 09/01/2007 - "Several drug companies have developed and evaluated hyperimmune polyclonal and monoclonal antibodies for the prevention of neonatal staphylococcal infection including 1) Altastaph by North American Biologics Inc., 2) Veronate by Inhibitex Inc., and 3) Pagibaximab by Biosynexus Inc, and Glaxo Smith Kline Inc. "
3.	Bacteremia 12/01/2007 - "aureus bacteremia received standard therapy plus either Altastaph at 200 mg/kg of body weight in each of two infusions 24 h apart or placebo. "
4.	Fever (Fevers) 12/01/2007 - "Compared to the control patients, the Altastaph recipients had a shorter median time to the resolution of fever (2 days and 7 days, respectively; P = 0.09) and a shorter length of hospital stay (9 days and 14 days, respectively; P = 0.03). "
5.	Body Weight (Weight, Body) 12/01/2007 - "aureus bacteremia received standard therapy plus either Altastaph at 200 mg/kg of body weight in each of two infusions 24 h apart or placebo. "

Related Drugs and Biologics

1.	Immunoglobulins (Immunoglobulin)
2.	Polysaccharides (Glycans)
3.	Immunoglobulin G (IgG)
4.	Monoclonal Antibodies
5.	pagibaximab
6.	Veronate

Related Therapies and Procedures

1.	Therapeutics
2.	Length of Stay